Merck KGaA (MKKGY) News Today $30.30 -1.35 (-4.27%) As of 01/31/2025 03:51 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200January 31 at 5:07 AM | insidermonkey.comMerck Stops Winrevair Study Early Amid Positive ResultsJanuary 31 at 4:34 AM | marketwatch.comDeutsche Bank Sticks to Their Buy Rating for Merck KGaA (0O14)January 31 at 4:34 AM | markets.businessinsider.comMerck to stop Phase 3 HYPERION trialJanuary 30 at 8:33 AM | markets.businessinsider.comMerck To Stop Phase 3 HYPERION Study EarlyJanuary 30 at 8:33 AM | markets.businessinsider.comMerck KGaA (OTCMKTS:MKKGY) Short Interest Up 4,075.0% in JanuaryMerck KGaA (OTCMKTS:MKKGY - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 16,700 shares, a growth of 4,075.0% from the December 31st total of 400 shares. Based on an average daily volume of 329,400 shares, the days-to-cover ratio is currently 0.1 days.January 29 at 6:55 AM | marketbeat.comMerck price target lowered to $125 from $130 at CitiJanuary 28, 2025 | markets.businessinsider.comMerck: FDA grants priority review to sNDA for WeliregJanuary 27, 2025 | markets.businessinsider.comMerck Gets FDA Priority Review of Welireg in Rare Adrenal TumorsJanuary 27, 2025 | marketwatch.comMerck, Eisai provide update on Phase 3 LEAP-015 trialJanuary 24, 2025 | markets.businessinsider.comMerck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer StudyJanuary 24, 2025 | marketwatch.comMerck and Opentrons to automate assay kits on custom workstationJanuary 24, 2025 | finance.yahoo.comMerck KGaA says high asset prices call for prudent M&A approachJanuary 23, 2025 | reuters.comMilliporeSigma Partners with Opentrons Labworks, Inc., Supporting Lab of the FutureJanuary 23, 2025 | financialpost.comMerck KGaA, Darmstadt, Germany Announces Launch of Caregiver Leave Benefit, Strengthening Inclusive Family-Friendly OfferingsJanuary 22, 2025 | financialpost.comExclusive-Kennedy Played Key Role in Vaccine Case Against MerckJanuary 19, 2025 | usnews.comMerck price target lowered to $122 from $130 at GuggenheimJanuary 17, 2025 | markets.businessinsider.comMerck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda ChallengesJanuary 15, 2025 | markets.businessinsider.comMerck & Company: Balancing Growth Prospects with Competitive Challenges in Oncology and ImmunologyJanuary 14, 2025 | markets.businessinsider.comMerck KGaA (OTCMKTS:MKKGY) Sees Large Increase in Short InterestMerck KGaA (OTCMKTS:MKKGY - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 16,700 shares, an increase of 4,075.0% from the December 15th total of 400 shares. Based on an average trading volume of 329,400 shares, the short-interest ratio is currently 0.1 days.January 13, 2025 | marketbeat.comMerck price target lowered to $120 from $125 at UBSJanuary 8, 2025 | markets.businessinsider.comMirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal CancerJanuary 8, 2025 | markets.businessinsider.comMerck to buy WuXi Biologics' Irish vaccine facility for $500 millionJanuary 7, 2025 | finance.yahoo.comMilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology PortfolioJanuary 6, 2025 | financialpost.comMerck KGaA (OTCMKTS:MKKGY) Short Interest UpdateMerck KGaA (OTCMKTS:MKKGY - Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 400 shares, a drop of 75.0% from the November 30th total of 1,600 shares. Based on an average trading volume of 280,200 shares, the short-interest ratio is currently 0.0 days.December 26, 2024 | marketbeat.comMerck reaches weight-loss drug deal worth up to $2 billion with China-based HansohDecember 18, 2024 | msn.comMerck KGaA (OTCMKTS:MKKGY) Sets New 1-Year Low - Here's WhyMerck KGaA (OTCMKTS:MKKGY) Hits New 12-Month Low - Here's WhyDecember 18, 2024 | marketbeat.comMerck Makes Another Play for Lucrative Obesity-Drug MarketDecember 18, 2024 | wsj.comMerck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 BillionDecember 18, 2024 | marketwatch.comMerck Enters Into Exclusive Global License Agreement With Hansoh Pharma For HS-10535December 18, 2024 | markets.businessinsider.comMerck in Pact for Chinese Obesity Drug in Nearly $2 Billion DealDecember 18, 2024 | msn.comMerck & Company’s Strategic Pivots and Growth Potential: A Buy Rating JustificationDecember 18, 2024 | markets.businessinsider.comDZ BANK AG Sticks to Its Buy Rating for Merck KGaA (0O14)December 3, 2024 | markets.businessinsider.comMerck reports ‘positive’ results from Phase 3 ZENITH trial evaluating WinrevairNovember 25, 2024 | markets.businessinsider.comKepler Capital Sticks to Its Buy Rating for Merck KGaA (0O14)November 16, 2024 | markets.businessinsider.comMerck KGaA Third Quarter 2024 Earnings: Misses ExpectationsNovember 16, 2024 | finance.yahoo.comMerck initiated with a Peer Perform at Wolfe ResearchNovember 14, 2024 | markets.businessinsider.comMerck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 BillionNovember 14, 2024 | msn.comMerck signs up to $3.3 billion cancer drug deal with China-based LaNovaNovember 14, 2024 | msn.comMerck KGaA stock falls on weak Q3, soft outlookNovember 14, 2024 | investing.comMerck KGaA, Darmstadt, Germany and Intel Launch Academic Research Program in Europe for More Sustainable Semiconductor ManufacturingNovember 7, 2024 | financialpost.comMerck's Unity-SC acquisition bolsters optoelectronic capabilityNovember 4, 2024 | msn.comKepler Capital Reaffirms Their Buy Rating on Merck KGaA (0O14)November 3, 2024 | markets.businessinsider.comMerck Tops Earnings Estimates but Lowers Full-Year GuidanceNovember 2, 2024 | msn.comMerck price target lowered to $110 from $125 at Wells FargoNovember 1, 2024 | markets.businessinsider.comMerck Narrows Sales Outlook With Gardasil Lagging in ChinaNovember 1, 2024 | msn.comMerck cuts FY24 adjusted EPS view to $7.72-$7.77 from $7.94-$8.04November 1, 2024 | markets.businessinsider.comMerck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda ThreatOctober 25, 2024 | seekingalpha.comMerck price target lowered to $130 from $140 at CitiOctober 25, 2024 | markets.businessinsider.comMerck: EC approves two new indications for KeytrudaOctober 25, 2024 | markets.businessinsider.com Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter. Email Address MKKGY Media Mentions By Week MKKGY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MKKGY News Sentiment▼0.080.69▲Average Medical News Sentiment MKKGY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MKKGY Articles This Week▼103▲MKKGY Articles Average Week Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Regeneron Pharmaceuticals News Today Zoetis News Today GSK News Today Takeda Pharmaceutical News Today UCB News Today Alnylam Pharmaceuticals News Today Teva Pharmaceutical Industries News Today Bayer Aktiengesellschaft News Today Merck KGaA News Today Royalty Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MKKGY) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
